MedTrace Logo

AVATR - Arteriovenous Access Thrombosis Removal With CAPERE Thrombectomy System

NCT04494035 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-09-13

No results posted yet for this study

Summary

A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the CAPERE® Thrombectomy System.

Conditions

  • Arteriovenous Graft Thrombosis

Interventions

DEVICE

CAPERE Thrombectomy System

Arteriovenous graft thrombectomy

Sponsors & Collaborators

  • Medtronic Endovascular

    lead INDUSTRY

Principal Investigators

  • Sebastian Mafeld, MD · University Health Network Toronto General

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2020-10-23
Completion
2020-10-23
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04494035 on ClinicalTrials.gov